Sonic Healthcare Limited (ASX:SHL): How Automated Laboratory Tracks Support Diagnostic Testing

Aditi Sarkar

13 October 2026 04:14 AM AEDT

Sonic Healthcare Limited (ASX:SHL): How Automated Laboratory Tracks Support Diagnostic Testing

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Sonic Healthcare uses laboratory instruments, information systems and specimen routing workflows to support diagnostic testing.
Barcode identification and automated handling help direct samples through preparation, analysis and storage.
FY2026 revenue reached AUD 10.9 billion, with underlying EBITDA of AUD 1.93 billion.
Equipment availability, quality assurance and reagent supply remain important operating considerations.

Sonic Healthcare Limited (ASX:SHL) provides pathology, clinical laboratory and diagnostic imaging services to doctors, hospitals and patients in several countries. Its laboratories handle specimens that must be identified, prepared, analysed and reported accurately. Automated track systems support parts of this workflow by connecting sample handling equipment with diagnostic instruments and laboratory information systems. Sonic Healthcare reported FY2026 revenue of AUD 10.9 billion and underlying EBITDA of AUD 1.93 billion, providing financial context for its international diagnostic operations.

How Specimens Move Through a Laboratory

Patient specimens generally arrive from collection centres, clinics and hospitals with identifying information attached. At laboratory reception, staff and equipment register samples, check their suitability and associate each container with the requested tests. Barcode-based tracking helps link a specimen to its laboratory record as it moves between processing stations. Sonic Healthcare (ASX:SHL) relies on coordinated collection, transport and laboratory processes to make test results available to referring clinicians.

For blood testing, preparation can include sorting, centrifugation and removal of tube caps before the sample reaches an analyser. Automated conveyance systems can reduce manual movement between compatible instruments. The configuration differs by laboratory, test category and local clinical requirements; not every sample follows the same automated route. Specialist procedures and tests requiring clinical judgement continue to involve appropriately trained laboratory personnel.

Integration With Diagnostic Instruments and Reporting

Clinical chemistry and immunoassay instruments measure selected substances in patient samples, while other departments handle haematology, microbiology, histopathology and molecular diagnostics. Laboratory information systems coordinate orders, specimen identification and result records. Where configured, rules can direct further testing after an initial result. For Sonic Healthcare (ASX:SHL), these connected processes create opportunities to standardise routine handling without replacing specialist review or medical oversight.

Automated refrigerated storage may retain eligible specimens for repeat analysis or additional authorised tests. However, storage duration and conditions depend on the specimen and test. Sonic Healthcare also operates across different health systems, making local laboratory governance, data access and accreditation requirements central to its operational design.

Operational Risks and Measures to Monitor

Track failures, analyser downtime and power interruptions can interrupt the movement of specimens and extend reporting times. Laboratories also depend on reagents, calibration materials and consumables that may be affected by delivery constraints. Quality-control checks, instrument maintenance and contingency procedures therefore remain necessary alongside automation. Sonic Healthcare (ASX:SHL) must coordinate these requirements while meeting clinical standards and safeguarding confidential patient information.

Relevant operating indicators include test volumes, turnaround times, staff productivity, instrument utilisation and the cost of providing services. Financial results add another perspective: FY2026 underlying net profit was AUD 621 million, according to the company’s annual report. These measures should be considered separately, since financial performance alone does not establish the effectiveness of a particular automated laboratory installation.

Key Insights

Laboratory automation is one component of Sonic Healthcare’s broader diagnostic service model. Sample identification, reliable instrument interfaces and timely clinical reporting are as significant as the mechanical handling of tubes. For Sonic Healthcare (ASX:SHL), maintaining quality, system availability and consistent processes across its laboratories remains important as testing needs and operating costs evolve.

FAQs

Q: What does Sonic Healthcare do?

A:It provides pathology, clinical laboratory and diagnostic imaging services to clinicians, hospitals and patients.

Q: What is an automated laboratory track system?

A:It is a specimen transport and routing arrangement that can connect preparation equipment, analysers and storage devices.

Q: Does automation eliminate manual laboratory work?

A:No. Specimen exceptions, specialised testing, quality management and clinical interpretation still require qualified personnel.

Q: What were Sonic Healthcare’s FY2026 revenue and underlying EBITDA?

A:The company reported revenue of AUD 10.9 billion and underlying EBITDA of AUD 1.93 billion.

Q: Which risks affect laboratory automation?

A:Equipment downtime, reagent availability, specimen identification errors, cybersecurity and quality-control failures can disrupt testing.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.